Pernix Therapeutics (PTX) Tops Q4 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Pernix Therapeutics (PTX) Target Price Lifted to $16 at Needham & Company
February 26, 2015 6:40 AM ESTNeedham & Company analyst Elliot Wilbur reiterated a Strong Buy and boosted his price target on Pernix Therapeutics (NASDAQ: PTX) to $16.00 (from $12.00)
Wilbur commented, "PTX closed out a transformational 2014 with solid 4Q14 financials that bolster our confidence in obtainment of 2015 guidance parameters. New Treximet... More
